Literature DB >> 6193623

Amikacin in the treatment of pulmonary tuberculosis.

B W Allen, D A Mitchison, Y C Chan, W W Yew, W G Allan, D J Girling.   

Abstract

Sensitivity tests on strains from 11 patients with pulmonary tuberculosis, previously treated with kanamycin and/or capreomycin, showed incomplete cross-resistance between amikacin and capreomycin but complete cross-resistance between amikacin and kanamycin. Treatment with amikacin of 4 patients with multiply resistant strains resulted in no response as assessed by sputum smears and cultures, but resistance emerged to amikacin, kanamycin and capreomycin. Amikacin has no role in the treatment of tuberculosis as it cannot be given as an alternative to kanamycin, has no advantages over it and is more expensive.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6193623     DOI： 10.1016/0041-3879(83)90035-1

Source DB:  PubMed          Journal:  Tubercle        ISSN： 0041-3879


  9 in total

1.  Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media.

Authors:  G E Pfyffer; D A Bonato; A Ebrahimzadeh; W Gross; J Hotaling; J Kornblum; A Laszlo; G Roberts; M Salfinger; F Wittwer; S Siddiqi
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

2.  Kanamycin susceptibility testing of Mycobacterium tuberculosis using Mycobacterium Growth Indicator Tube and a colorimetric method.

Authors:  I Bastian; L Rigouts; J C Palomino; F Portaels
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis.

Authors:  G J Alangaden; B N Kreiswirth; A Aouad; M Khetarpal; F R Igno; S L Moghazeh; E K Manavathu; S A Lerner
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

4.  Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis.

Authors:  Courtney E Maus; Bonnie B Plikaytis; Thomas M Shinnick
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 5.  Respiratory and allergic disease. II. Chronic obstructive airways disease and respiratory infections.

Authors:  K F Chung; P J Barnes
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-09

6.  Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice?

Authors:  N Lounis; B Ji; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

7.  Molecular genetics of Mycobacterium tuberculosis resistant to aminoglycosides and cyclic peptide capreomycin antibiotics in Korea.

Authors:  Hum Nath Jnawali; Heekyung Yoo; Sungweon Ryoo; Kwang-Jun Lee; Bum-Joon Kim; Won-Jung Koh; Chang-Ki Kim; Hee-Jin Kim; Young Kil Park
Journal:  World J Microbiol Biotechnol       Date:  2013-01-18       Impact factor: 3.312

Review 8.  Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.

Authors:  Ronald G Hall; Richard D Leff; Tawanda Gumbo
Journal:  Pharmacotherapy       Date:  2009-12       Impact factor: 4.705

Review 9.  Drug treatment of tuberculosis--1992.

Authors:  P T Davidson; H Q Le
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.